Conference Reports for NaTaP

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria  april 22-26 Back

HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer       EASL: HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer / Global Hepatitis Burden / HCV Linked to Increased Cancer Risks / HCV Screening in Prisons Cost-Effective   EASL: THE GLOBAL AND REGIONAL BURDEN OF LIVER DISEASE, 2013: deaths due to HCV doubled from 1990 to 2013 - (04/27/15)   EASL: CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION (Kaiser)....HCV Linked to Increased Cancer Risks/Not just liver cancer - (04/27/15)   EASL: Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks after Treatment With Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin in HCV Genotype 1 Patients With Cirrhosis - (04/24/15)   EASL: A Systematic Review of Viral Hepatitis B and C Testing in Europe: shortage of hepatitis screening studies across Europe/barrier to diagnosis, early treatment & prevention - (04/29/15)......there are crucial gaps in our knowledge on hepatitis B and C testing - we do not yet have enough information to plan effective public health responses in Europe.....same problem exists in the US as well   EASL: CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?: EVIDENCE FROM THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM - (04/28/15)   EASL: HCV Screening/treatment in UK Prisons Can be Cost-Effective - IS INCREASED HCV CASE-FINDING COMBINED WITH 8 OR 12 WEEK INTERFERON-FREE DIRECT-ACTING ANTIVIRAL TREATMENT COST EFFECTIVE IN UK PRISONS? A COST UTILITY ANALYSIS INCLUDING TREATMENT AS PREVENTION BENEFITS - (04/27/15)   EASL: Time Course of Hepatic Improvement using the HepQuant® (HQ)-SHUNT Function Test during and after Treatment with Ledipasvir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation - (04/29/15)   EASL: Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension - (04/29/15)   ------------------------   EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)   EASL: SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment - (04/31/15)   EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States - (04/28/15)   EASL: The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15)   EASL: Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin Compared to No Treatment in the United States - (04/31/15)   -------------------------------   EASL: Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER - (04/31/15)   EASL: EASL Recommendations on Treatment of Hepatitis C 2015 - (04/22/15)   Global HCV: The case for keeping viral hepatitis in the SDGs (UN's Sustainable Development Goals) - (04/15/15)   EASL: 8 HCV DAA Studies in African-Americans - (05/04/15)   EASL: HCV Reinfection in Phase 3 Studies of Sofosbuvir - (04/29/15)   Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study - SVR - majority of patients symptoms persistently disappeared - (04/15/15)   Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure - HCV traces in PBMC of 3/54 SVRs disappear after 9 yrs - (04/15/15)   published - The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection - (05/11/15)   4 HCV Cost-Effectiveness Studies Just Published; Costs for New Cancer/Cholesterol, Diabetes Drugs - New Model to Fund Healthcare - (04/01/15)   CDC Reports 350% Surge in HCV Infections Among Young in Apalachia; federal ineptitude & refusal to respond to HCV persists - (05/06/15)   Federal Healthcare Solution Needed - Specialty drugs cost increasing for cancers, diabetes, heart disease, autoimmune diseases which are not curable - (04/15/15)   EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria April 22-26